Professor Murray Brunt reflects on three decades of progress in Breast Cancer Treatment
Professor Murray Brunt delivered his inaugural lecture, “From ABC to FAST Forward for the Future: A Journey in Academic Clinical Breast Oncology,” on 14 June 2023 at the Denise Coates Building, Keele University.
The lecture reflected on more than 30 years of developments in breast cancer treatment and research, drawing on Professor Brunt’s own career as a Consultant Clinical Oncologist and his involvement in major clinical trials.
A career shaped by advances in Breast Cancer Care
Professor Brunt began working as a Consultant Clinical Oncologist at the North Staffordshire Royal Infirmary in 1991.
Since then, breast cancer treatment has changed considerably, with new therapies, improved understanding of existing treatments and increasingly personalised approaches helping to improve outcomes for patients.
His lecture explored this evolution through some of the key research studies and clinical developments that have shaped his academic career.
The talk was designed to be accessible to specialists, scientists and those without a detailed knowledge of breast cancer, providing a broad view of how research has transformed treatment over several decades.
Developments in Hormone Therapy and Chemotherapy
When Professor Brunt began his consultant career, tamoxifen had relatively recently been shown to offer important benefits in breast cancer treatment.
Over subsequent years, hormone therapies developed significantly, with new treatment options and a better understanding of which patients were most likely to benefit.
Research has also increasingly focused on why some cancers become resistant to treatment and how newer drugs might help overcome that resistance.
Chemotherapy has undergone similar changes. Early clinical trials established its role in reducing the risk of breast cancer returning, but treatment was often accompanied by significant side effects.
Today, improvements in chemotherapy, supportive care and patient selection mean clinicians are better able to identify who is most likely to benefit while managing the impact of treatment more effectively.
Advancing Breast Radiotherapy
Radiotherapy research has been a particularly important part of Professor Brunt’s academic career.
The UK has played a leading role in breast cancer radiotherapy research, helping to develop treatment approaches that are more precise and increasingly tailored to individual patients.
Professor Brunt’s lecture traced the transition from relatively standardised approaches towards more refined and personalised radiotherapy.
His continuing research in this area reflects the ongoing effort to make treatment both effective and more convenient for patients.
From the Laboratory to the Clinic
The lecture also explored the emergence of new targeted therapies developed through scientific research.
One notable example was Herceptin, which transformed treatment for some patients with HER2-positive breast cancer and demonstrated the potential of translating laboratory discoveries into effective clinical treatments.
These “bench to bedside” developments have become an increasingly important part of modern oncology, contributing to a much wider range of treatments than were available when Professor Brunt began his career.
Looking to the future of Breast Oncology
Professor Brunt’s inaugural lecture highlighted just how rapidly breast cancer care has evolved during his career.
From advances in hormone therapy and chemotherapy to increasingly sophisticated radiotherapy and targeted treatments, research has played a central role in improving care and outcomes.
The event also provided an opportunity to recognise the contribution of clinical research carried out locally, nationally and internationally, while looking ahead to the discoveries that may shape the next generation of breast cancer treatment.
The Wade Charitable Foundation was pleased to support an event celebrating Professor Murray Brunt’s academic journey and his continuing contribution to research in clinical breast oncology.